Pioneers in Cell and Gene Therapy Andelyn Biosciences is a gene therapy contract development and manufacturing organization born out of Nationwide Children's Hospital and based in Columbus, OH, where the first FDA-approved systemic gene therapy was discovered and worked on by members of our current team. The name “Andelyn” was chosen as a hybrid of two patients who participated in pivotal Phase I clinical trials at Nationwide Children’s Hospital – Andrew and Evelyn. Andrew received the first U.S. investigational gene therapy for Duchenne muscular dystrophy in 2006. Evelyn received experimental gene therapy for spinal muscular atrophy in 2015. “Andelyn” combines their names, representing all the families who have courageously participated in the research that makes today’s gene therapies possible and reminding us that patients are at the heart of everything we do.